Physician profile
William J Roth
NPI 1902879307
$2,264.40
in general payments reported to CMS, 2019-2025
24 companies · $703 in 2025
The $703 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $99.71 · 2021: $11.06 · 2022: $464 · 2023: $280 · 2024: $563 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Education: $63.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.30 |
| Education | $63.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $455.41 | 2022-2023 | Xeomin |
| Janssen Biotech, INC. | $237.16 | 2024-2025 | Tremfya |
| Abbvie INC. | $192.01 | 2022-2025 | |
| Leo Pharma INC. | $189.35 | 2020-2025 | Anzupgo, Adbry |
| Genzyme Corporation | $166.07 | 2023-2025 | |
| Sensus Healthcare, INC. | $131.45 | 2019 | |
| Arcutis Biotherapeutics, INC. | $116.67 | 2024-2025 | Zoryve |
| Pfizer INC. | $107.30 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $91.90 | 2023-2025 | Odomzo, Blu-U |
| Amgen INC. | $87.73 | 2020 | |
| Galderma Laboratories, L.P. | $74.48 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Organon LLC | $62.51 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $61.02 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $60.78 | 2023-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $51.10 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $24.54 | 2025 | Ycanth |
| Teva Pharmaceuticals USA, INC. | $23.69 | 2024 | Simlandi |
| Blueprint Medicines Corporation | $23.02 | 2024 | Ayvakit |
| Ucb, INC. | $22.68 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.22 | 2024 | Cabtreo |
| Regeneron Healthcare Solutions, INC. | $20.57 | 2025 | Dupixent |
| Sumitomo Pharma America, INC. | $16.50 | 2025 | Gemtesa |
| Cipher Pharmaceuticals US LLC | $15.83 | 2025 | Natroba, Spinosad |
| Helsinn Therapeutics (U.S.), INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.